Overview
Investment portfolio
| NAME | DATE | SIZE | |
|---|---|---|---|
Verrica Pharmaceuticals | Nov 2025Led | $50 MOther Equity | |
Blue Earth Therapeutics | Oct 2024Participated | $77 MSeries A | |
SalioGen Therapeutics | Jan 2022Participated | $115 MSeries B | |
LEXEO Therapeutics | Sep 2021Participated | $100 MSeries B | |
Xalud Therapeutics | Aug 2021Led | $30 MSeries C | |
SalioGen Therapeutics | Mar 2021Led | $20 MSeries A | |
PatientsLikeMe | Feb 2021Led | $26 MOther Equity | |
LEXEO Therapeutics | Jan 2021Participated | $85 MSeries A | |
Taysha Gene Therapies | Aug 2020Participated | $95 MSeries B | |
Taysha Gene Therapies | Apr 2020Led | $30 MSeed | |
ArcherDX | Dec 2019Participated | $55 MSeries C | |
Landos Biopharma | Aug 2019Participated | $60 MSeries B | |
Verrica Pharmaceuticals | Nov 2025Led | $50 MOther Equity | |
Blue Earth Therapeutics | Oct 2024Participated | $77 MSeries A | |
SalioGen Therapeutics | Jan 2022Participated | $115 MSeries B | |
LEXEO Therapeutics | Sep 2021Participated | $100 MSeries B | |
Xalud Therapeutics | Aug 2021Led | $30 MSeries C | |
SalioGen Therapeutics | Mar 2021Led | $20 MSeries A | |
PatientsLikeMe | Feb 2021Led | $26 MOther Equity | |
LEXEO Therapeutics | Jan 2021Participated | $85 MSeries A | |
Taysha Gene Therapies | Aug 2020Participated | $95 MSeries B | |
Taysha Gene Therapies | Apr 2020Led | $30 MSeed | |
ArcherDX | Dec 2019Participated | $55 MSeries C | |
Landos Biopharma | Aug 2019Participated | $60 MSeries B |
Insights
Time horizon
View by
Deal Distribution
| Round type | Led deals | Participated deals |
|---|---|---|
| Seed | 1 | 0 |
| Series A | 2 | 2 |
| Series B | 1 | 6 |
| Series C+ | 1 | 1 |
| Other Equity | 2 | 0 |
Monthly Deal Activity
| Month | Deals |
|---|---|
| Mar '18 | 1 |
| Apr '18 | 0 |
| May '18 | 0 |
| Jun '18 | 0 |
| Jul '18 | 0 |
| Aug '18 | 0 |
| Sep '18 | 0 |
| Oct '18 | 1 |
| Nov '18 | 0 |
| Dec '18 | 0 |
| Jan '19 | 1 |
| Feb '19 | 0 |
| Mar '19 | 0 |
| Apr '19 | 0 |
| May '19 | 1 |
| Jun '19 | 0 |
| Jul '19 | 0 |
| Aug '19 | 1 |
| Sep '19 | 0 |
| Oct '19 | 0 |
| Nov '19 | 0 |
| Dec '19 | 1 |
| Jan '20 | 0 |
| Feb '20 | 0 |
| Mar '20 | 0 |
| Apr '20 | 1 |
| May '20 | 0 |
| Jun '20 | 0 |
| Jul '20 | 0 |
| Aug '20 | 1 |
| Sep '20 | 0 |
| Oct '20 | 0 |
| Nov '20 | 0 |
| Dec '20 | 0 |
| Jan '21 | 1 |
| Feb '21 | 1 |
| Mar '21 | 1 |
| Apr '21 | 0 |
| May '21 | 0 |
| Jun '21 | 0 |
| Jul '21 | 0 |
| Aug '21 | 1 |
| Sep '21 | 1 |
| Oct '21 | 0 |
| Nov '21 | 0 |
| Dec '21 | 0 |
| Jan '22 | 1 |
| Feb '22 | 0 |
| Mar '22 | 0 |
| Apr '22 | 0 |
| May '22 | 0 |
| Jun '22 | 0 |
| Jul '22 | 0 |
| Aug '22 | 0 |
| Sep '22 | 0 |
| Oct '22 | 0 |
| Nov '22 | 0 |
| Dec '22 | 0 |
| Jan '23 | 0 |
| Feb '23 | 0 |
| Mar '23 | 0 |
| Apr '23 | 0 |
| May '23 | 0 |
| Jun '23 | 0 |
| Jul '23 | 0 |
| Aug '23 | 0 |
| Sep '23 | 0 |
| Oct '23 | 0 |
| Nov '23 | 0 |
| Dec '23 | 0 |
| Jan '24 | 0 |
| Feb '24 | 0 |
| Mar '24 | 0 |
| Apr '24 | 0 |
| May '24 | 0 |
| Jun '24 | 0 |
| Jul '24 | 0 |
| Aug '24 | 0 |
| Sep '24 | 0 |
| Oct '24 | 1 |
| Nov '24 | 0 |
| Dec '24 | 0 |
| Jan '25 | 0 |
| Feb '25 | 0 |
| Mar '25 | 0 |
| Apr '25 | 0 |
| May '25 | 0 |
| Jun '25 | 0 |
| Jul '25 | 0 |
| Aug '25 | 0 |
| Sep '25 | 0 |
| Oct '25 | 0 |
| Nov '25 | 1 |
| Dec '25 | 0 |
| Jan '26 | 0 |
| Feb '26 | 0 |
| Mar '26 | 0 |
| Apr '26 | 0 |
| May '26 | 0 |
| Jun '26 | 0 |
| Jul '26 | 0 |
| Aug '26 | 0 |
| Sep '26 | 0 |
| Oct '26 | 0 |
Sector Breakdown
A deal can appear in multiple sectors, so sector totals may overlap. Capital represents disclosed total round sizes, not fund cheque sizes.
| Sector | Deals |
|---|---|
| Health & Life Sciences | 16 |
| Data, Analytics & IT | 1 |
| Space & Frontier Tech | 1 |
Deal Size Distribution
Undisclosed round sizes are excluded. Capital represents total round sizes, not fund cheque sizes.
| Round size band (USD) | Deals |
|---|---|
| <$5M | 0 |
| $5M-$10M | 0 |
| $10M-$25M | 2 |
| $25M-$50M | 5 |
| $50M-$100M | 7 |
| $100M-$250M | 2 |
| $250M-$500M | 0 |
| $500M-$1B | 0 |
| $1B+ | 0 |
Deals By Geography
Top 2 of 2 regions; European countries are grouped as Europe.
| Region | Deals |
|---|---|
| United States | 15 |
| Europe | 1 |
Co-Investors
Bubble size = shared deals
Click a bubble to open that fund in a new tab.
Shows up to 20 co-investors ranked by shared deals. Deals may be shared with multiple funds, so rows overlap. Capital is total round size, not fund cheque size.
| Co-investor | Shared deals |
|---|---|
| Perceptive Advisors | 4 |
| Sands Capital | 4 |
| Boulder Ventures | 3 |
| Invus | 3 |
| Longwood Fund | 3 |
| Woodline Partners | 3 |
| Alexandria Venture Investments | 2 |
| ArrowMark Partners | 2 |
| D1 Capital Partners | 2 |
| Fidelity Management & Research Company | 2 |
| Janus Henderson Investors | 2 |
| Longitude Capital | 2 |
| Lundbeckfond Ventures | 2 |
| Omega Funds | 2 |
| Peierls Foundation | 2 |
| Soleus Capital | 2 |
| Alta Partners | 1 |
| Alzheimer's Drug Discovery Foundation | 1 |
| BlackRock | 1 |
| Bracco Imaging | 1 |
Investment Strategy
| Category | Deals (count) | Share (%) |
|---|---|---|
| Led | 7 | 44% |
| Participating | 9 | 56% |
| Category | Deals (count) | Share (%) |
|---|---|---|
| Single-lead | 3 | 43% |
| Co-led | 4 | 57% |
Team
Director
SVP Business Development & Portfolio Management
President,Chairman & Chief Executive Officer
President
